E.E. Geduld’s Cymabay Therapeutics CBAY Stock Holding History

E.E. Geduld’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-20,000	Closed	-$138K	–	317
2015 Q1	$138K	Sell	20,000 -10,000	-33%	-$96K	0.09%	181
2014 Q4	$295K	Buy	30,000 +5,000	+20%	+$40.2K	0.16%	107
2014 Q3	$171K	Buy	+25,000	New	+$154K	0.12%	148

Other funds holding CBAY

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

E.E. Geduld's CBAY Position: Q2 2015 in Review

E.E. Geduld sold out of Cymabay Therapeutics (CBAY) in Q2 2015, closing a stake of 20,000 shares — an estimated $138K sold.

E.E. Geduld first reported a position in CBAY in Q3 2014 and held it in 3 quarters. The position peaked at $295K in Q4 2014. 29 funds tracked by Wall St. Rank hold CBAY as of Q2 2015.

E.E. Geduld reported no remaining Cymabay Therapeutics position as of Q2 2015 after selling out during the quarter.
E.E. Geduld sold 20,000 Cymabay Therapeutics shares in Q2 2015, an estimated $138K.
E.E. Geduld first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 3 quarters.
E.E. Geduld's Cymabay Therapeutics position peaked at $295K in Q4 2014.
29 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2015.

Based on E.E. Geduld's 13F filing for Q2 2015, filed 7 Aug 2015.